Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.
Koen ZwartSietske C M W van NassauFrederieke H van der BaanMiriam KoopmanPetur SnaebjornssonAnna J van GestelGeraldine R VinkJeanine M L RoodhartPublished in: British journal of cancer (2024)
This real-world cohort of mCRC patients treated with encorafenib-cetuximab showed a clinically relevant efficacy-effectiveness gap for OS. The chance of survival benefit from encorafenib-cetuximab in patients with brain metastases and/or WHO performance status ≥2 is negligible as neither efficacy nor effectiveness has been demonstrated.